Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has presented the early-stage clinical data from its GD2-SADA PRIT trial at the ...

Over the past 3 months, 7 analysts have published their opinion on Y-mAbs Therapeutics (NASDAQ:YMAB) stock. These analysts are typically employed by large Wall Street banks and tasked with ...

The duration of the virtual Radiopharmaceutical R&D update is expected to be 90 minutes. A live audio webcast of the call will be available on the Investor Relations section of the Company’s website ...

(RTTNews) - Biopharmaceutical company Y-mAbs Therapeutics, Inc. (YMAB) announced Thursday that Chief Financial Officer Bo Kruse has notified the Company of his resignation. Y-mAbs has commenced a ...

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and ...

"One word of truth outweighs the world.”― Aleksandr I. Solzhenitsyn Y-mAbs Therapeutics, Inc. is a New York City based commercial stage biopharmaceutical concern focused on the development of ...

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of radioimmunotherapy and antibody based therapeutic products for the ...